Welcome to our dedicated page for Tevogen SEC filings (Ticker: TVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tevogen Bio Holdings Inc. (TVGN) SEC filings page on Stock Titan aggregates the company’s official disclosures from the U.S. Securities and Exchange Commission, offering a structured view into this clinical-stage biotechnology issuer’s regulatory record. As a Nasdaq-listed company, Tevogen files periodic reports and current reports that detail its financial performance, operating strategy, and material events.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, management’s discussion and analysis, and commentary on Tevogen’s capital-efficient, cost-disciplined business model. For a company focused on precision T cell therapies and AI-enabled drug discovery, these filings provide context on research and development spending, general and administrative expenses, and non-GAAP measures such as adjusted loss from operations that Tevogen uses to describe operational performance.
Current reports on Form 8-K capture significant events, including listing and compliance matters. For example, Tevogen disclosed via Form 8-K that it received a Nasdaq notice regarding non-compliance with the $1.00 per share minimum bid price requirement, outlining the applicable compliance period and potential paths to regain compliance. Such filings help investors understand listing status and associated timelines.
The filings page also offers access to information related to equity structure, warrants, and other securities, as well as any proxy materials and, where applicable, insider transaction reports on Form 4. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as changes in operating loss, capital structure, or risk disclosures. Real-time updates from EDGAR ensure that new TVGN filings, from 10-Qs to 8-Ks, appear promptly with accessible explanations for investors analyzing Tevogen’s financial and regulatory trajectory.
Tevogen Inc. (TVGN) stated that on September 9, 2026 it received written notice from Nasdaq that it has regained compliance with the $15 million minimum market value of publicly held shares requirement under Nasdaq Listing Rule 5450(b)(2&3)(C) for continued listing on the Nasdaq Global Market. Nasdaq informed the company that the compliance matter is now closed.
Tevogen Inc. (TVGN) reported results of its August 24, 2026 annual stockholder meeting and related governance changes. Stockholders approved an amendment to the Tevogen Inc. 2024 Omnibus Incentive Plan, increasing the shares of common stock available for issuance under the plan by 100,000,000.
Stockholders also approved a Certificate of Amendment to the Certificate of Incorporation, filed on August 26, 2026, to permit stockholders to act by written consent in lieu of a meeting, effective upon filing. As of the July 23, 2026 record date, there were 6,416,540 shares outstanding, with 5,956,141 shares represented at the meeting, constituting a quorum. Two Class II directors were elected and KPMG LLP was ratified as independent auditor for 2026.
Tevogen Inc reported continuing losses as it advances its cell-therapy and AI-driven precision medicine programs. For the six months ended June 30, 2026, the company recorded a net loss of $11.2 million, improved from $15.9 million a year earlier, driven largely by a sharp reduction in general and administrative expenses to $4.6 million from $9.9 million. Research and development spending rose modestly to $6.4 million, reflecting ongoing work on lead candidate TVGN 489 and the broader pipeline.
Liquidity remains tight. Cash was $1.1 million at June 30, 2026, against $13.6 million in total liabilities and a stockholders’ deficit of $8.9 million. The company is relying on an unsecured related-party credit facility with a $6.4 million balance and $11.0 million still available, plus a remaining $7.0 million grant commitment from KRHP and an at-the-market equity program capped at $50 million. Management believes these sources will fund operations for at least 12 months but does not plan to initiate another clinical trial until it secures additional financing.
Tevogen executed a 1-for-50 reverse stock split in March 2026 and issued $3.0 million of pre-funded warrants and significant equity awards, resulting in substantial non-cash stock-based compensation of $6.1 million in the first half of 2026.
Tevogen Inc. will hold its 2026 annual stockholders meeting virtually on August 24, 2026 at 1:30 p.m. Eastern Time to elect two Class II directors, ratify KPMG LLP as independent auditor for the year ending December 31, 2026, amend its 2024 Equity Incentive Plan, and approve a charter amendment permitting stockholder action by written consent. Stockholders of record as of July 23, 2026 may vote online, by phone, mail, or during the webcast using a 16-digit control number.
The equity plan proposal would increase shares reserved for awards by 100,000,000, to 103,179,028, roughly 15.6 times the 6,416,540 shares outstanding as of the record date, and could be heavily used for executive and director grants. Tevogen is a Nasdaq-listed “controlled company”: CEO and chair Dr. Ryan Saadi holds 57.8% of voting power, and directors and officers together hold 65.6%. Recent related-party financings include multiple preferred stock series, a $36.0 million credit facility and prefunded warrants with the Patel Family, plus large long-term equity awards to senior management.
Tevogen Bio Holdings Inc., a Delaware corporation, has amended its Certificate of Incorporation to change its name to Tevogen Inc. A Certificate of Amendment was filed on July 29, 2026, and the name change became effective on July 30, 2026. The board also approved a conforming amendment to the Amended and Restated Bylaws, with no other bylaw changes.
The company’s common stock, par value $0.001 per share, and public warrants, exercisable at $575 per share, continue to trade on the Nasdaq Global Market under their existing ticker symbols. The CUSIP numbers 88165K200 for common stock and 88165K119 for warrants are unchanged, and the name change does not affect the rights of security holders.
Tevogen Bio Holdings Inc. is soliciting proxies for its virtual 2026 annual meeting on August 24, 2026. Stockholders will vote on electing two Class II directors, ratifying KPMG as auditor, a major increase to the 2024 equity plan, and a charter amendment permitting stockholder action by written consent.
Proposal 3 seeks to raise the 2024 Plan share reserve by 100,000,000 to 103,179,028 shares, an amount equal to about 15.6 times the 6,416,540 shares of common stock outstanding as of July 22, 2026, which the company acknowledges could significantly dilute non-award holders and increase insider voting power. As of the record date, directors and executive officers held about 65.6% of outstanding shares, including CEO and Chair Dr. Ryan Saadi’s 57.8% stake; Tevogen is treated as a Nasdaq “controlled company” and does not maintain independent compensation or nominating committees.
The proxy also details extensive related-party financing with the Patel Family, including preferred stock classes, a $36.0 million credit facility, prefunded warrants with a 9.99% beneficial ownership cap, and grants and consulting/equity arrangements. Executive compensation is heavily equity-based, highlighted by a 2024 special RSU grant to Dr. Saadi representing roughly 10% of the company’s fully diluted common stock.
Tevogen Bio Holdings Inc. insider Dr. Ryan H. Saadi reports beneficial ownership of 3,709,567 shares of common stock, representing 59.7% of the class. He holds sole voting power over 3,705,689 shares and sole dispositive power over 1,938,710 shares, with an additional 3,878 shares held with shared voting and dispositive power through his spouse.
On July 10, 2026, Dr. Saadi received a grant of 1,220,000 shares of Restricted Stock as compensation for his service as Chairman and Chief Executive Officer under the company’s 2024 plan. These shares carry voting rights but are non‑transferable and subject to forfeiture, vesting in four equal annual installments beginning on the seventh anniversary of the grant, with full acceleration upon death or disability. The ownership percentage is based on 6,215,107 shares of common stock outstanding as of July 14, 2026.
Sordillo Victor J. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. director Victor J. Sordillo received a grant of 40,000 shares of restricted common stock at no cost under the 2024 Omnibus Incentive Plan. The award vests in three equal installments tied both to service-based anniversaries and aggregate revenue milestones of $50 million, $100 million, and $150 million since the grant date, conditioned on his continued service. Following this grant, Sordillo directly holds 51,539 shares of Tevogen Bio common stock.
Saadi Ryan H. reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. disclosed that Chief Executive Officer Ryan H. Saadi received a grant of 1,220,000 shares of restricted common stock at $0.0000 per share under the 2024 Omnibus Incentive Plan. The award will vest in four equal annual installments commencing on July 10, 2033, contingent on his continued service. Following the grant, he holds 3,705,689 shares directly, plus 3,878 shares indirectly through his wife.
PODLOGAR SUSAN M reported acquisition or exercise transactions in this Form 4 filing.
Tevogen Bio Holdings Inc. granted director Susan M. Podlogar 40,000 shares of restricted common stock at no cash cost under its 2024 Omnibus Incentive Plan. The award vests in three equal installments, each requiring both a service condition and company revenue milestones of $50 million, $100 million, and $150 million in aggregate revenue since the grant date. Following this grant, Podlogar directly holds 48,678 shares of common stock.